Latest Guardant Health News & Updates

See the latest news and media coverage for Guardant Health. We track all announcements, press releases, and industry mentions in real time, all in one place.

Guardant Health

Blood-based precision oncology company

guardanthealth.com

Headquarters: Palo Alto, United States
Founded year: 2012
Company type: Public company
Number of employees: 4,900–5,000
Industry: Biotechnology & Medical Research

Last updated September 30

Latest news about Guardant Health

In short: Guardant Health expanded Shield access, gained approvals, raised guidance, and faced patent losses.

Company announcements

September 14 Guardant Health

Guardant Health gains EviCore coverage for its Shield blood test

EviCore by Evernorth will cover the Shield colorectal cancer screening test starting January 1, 2027, impacting over 94 million eligible lives across 23 states.

September 4 Guardant Health

Guardant Health secures FDA approval for breast cancer companion diagnostic

The liquid biopsy identifies ESR1 mutations in patients treated with AstraZeneca's camizestrant, enabling earlier therapy switching that improves progression-free survival by 56 percent.

September 1 Guardant Health

Guardant Health secures major insurance coverage for its cancer test

Carelon Health Services will cover the FDA-approved Shield blood test starting November 15. This expansion brings total covered lives to approximately 90 million eligible U.S. patients.

July 30 Guardant Health

Guardant Health reports Q2 revenue growth of 44%

Revenue reached $335 million. Screening surged 257%. The company raised full-year guidance and highlighted FDA approvals for Guardant360.

Media coverage

September 30 Florida Politics

American Cancer Society adds Guardant Health's Shield blood test to colorectal cancer screening guideline

By making colorectal cancer screening more accessible with a blood-based option in conjunction with other established methodologies, we can get people screened...

September 17 Yahoo Finance

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer. The decision makes...

September 14 Yahoo Finance

Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in...

September 3 FierceBiotech

Guardant wins FDA nod for diagnostic guiding use of AstraZeneca's Etcamah

Hot on the heels of the approval for AstraZeneca's breast cancer drug Etcamah, Guardant Health has been given the green light for its companion diagnostic...

Never miss news about Guardant Health

Track Guardant Health and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Guardant Health competitors & trending companies

Browse news for competitors to Guardant Health and other trending companies.